Introduction
Human granulocyte colony-stimulating factor (G-CSF) is a 20 KD glycoprotein which consists of 174 amino acids. The gene is located on chromosome 17. Pharmacological G-CSF can augment and accelerate the proliferation of granulopoiesis in the bone marrow and shortens the maturation time of granulopoietic cells (Lord et al. 1989 ). G-CSF also can release the produced and stored post-mitotic leukocytes from the bone marrow microenvironment into the blood (Bronchud et al. 1988 ; Kerst et al. 1993; Chatta et al. 1994) . Within a few hours this can result in a significant increase in the number of white blood cells (WBCs). Recruited into the blood are predominantly neutrophils but also monocytes and lymphocytes can increase in their number ; Gabrilove et al. 1988 ; Kerst et al. 1993 ). Peak WBC counts after a single dose of G-CSF are reached after approximately 12 hours. When G-CSF is administered for several days a mobilization of hematopoietic stem cells into the blood occurs (Dührsen et al. 1988 ).
Since the 1960s, it is known that the morbidity and mortality from infection in cancer patients who receive chemotherapy depends on the duration and severity of leukopenia or neutropenia (Bodey et al. 1966 ). The success of antibiotic treatment in leukopenic patients depends on the leukocyte recovery (Link et al. 1994 ). The transplantation of autologous hematopoietic stem cells can rescue the host hematopoietic functions after high-dose chemotherapy. High-dose chemotherapy showed favorable disease control and survival in patients with mutiple myeloma or lymphoma (Philip et al. 1995; Attal et al. 1996 ; Barlogie et al. 1997 ). The use of mobilized autologous blood stem cells (Molineux et al. 1990 ; Pettengell et al. 1993 ) has almost completely replaced the use of For personal use only. on . by guest www.bloodjournal.org From autologous bone marrow as a graft because of a faster engraftment (Beyer et al. 1995; Schmitz et al. 1996) . 
Patients and methods

Patients
The investigation was performed in 57 patients with multiple myeloma. Thirty-five patients (61%) were male, 22 patients (39%) were female. The median age was 53 years (range 36-68 years). Prior therapy was limited in these patients. In 52/57 patients (91%) the duration of prior chemotherapy was ≤ 12 months with a maximum of 6 months of prior alkylating therapy. The median duration of prior alkylating therapy for all patients was 1 month and 28/57 patients (49%) had received no prior alkylating therapy. Before high-dose therapy, the patients had received a median of 6 cycles of chemotherapy (range 2-25 cycles). Radiation therapy had been given to 19 patients (33%). The radiation field had been restricted to smaller areas in order not to adversely effect later stem cell mobilization and comprised singular skeletal lesions or a median of 5 (range 3-7) vertebral bodies. The patients gave informed consent to their treatment, which uniformly consisted of high-dose chemotherapy, autologous blood stem cell transplantation and the identical G-CSF regimen. All patients were treated at the Med.
Klinik-Innenstadt in Munich.
Blood stem cell mobilization, harvesting, processing and cryopreservation
In the vast majority of patients (96%), the IEV regimen with G-CSF was used for stem cell mobilization. The IEV regimen consists of ifosfamide 2500 mg/m² intravenously day 1-3, epirubicin 100 mg/m² intravenously day 1 and etoposide 150 mg/m² intravenously day 1-3 followed by G-CSF (filgrastim; Amgen, Thousand Oaks, CA, USA) at a dose of From the day after transplantation, G-CSF was given daily at a dose of 5 µg/kg until post-nadir WBC counts were between 5000/µL and 10000/µL.
High-dose therapy, G-CSF and blood stem cell transplantation
Supportive care
All the patients were hospitalized during high-dose therapy, autograft and the posttransplant phase and received the same supportive care. The antimicrobial prophylaxis consisted of the following: From the time of autograft until neutrophil recovery ciprofloxacin 2 x 250 mg daily was given. Oral amphotericin B suspension 4 x 1 mL was given during the entire hospital stay or alternatively, in case of oral amphotericin intolerance, oral fluconazole 1 x 100 mg daily. Pneumocystis carinii pneumonitis prophylaxis was given during the administration of high-dose chemotherapy with trimethoprim/sulfamethoxazole 160 mg/800 mg 2 x 1 daily, was stopped before transplantation and was continued after hospital discharge with 2 x 1 on two consecutive days per week for 6 months. In case of trimethoprim/sulfamethoxazole intolerance, alternatively a pentamidine inhalation with 300 mg was performed every 4 weeks for 6 months from autograft. Intravenous acyclovir was given at a dose of 2 x 500 mg from the start of high-dose therapy until neutrophil recovery. Red blood cell products and single-donor platelets were substituted to maintain a hemoglobin level above 80 g/L and a platelet count above 10000/µL. All blood cell products were CMV negative, were irradiated with 30 Gy and were transfused through a leukocyte reduction filter. Empirical intravenous antimicrobial therapy was started during neutropenia after a single oral temperature >38.5°C or when fever >38.0°C was present over at least one hour and 
Assessment of hematopoietic recovery and infection
Neutrophil recovery was defined as the first of three days with a neutrophil count above 500/µL from the day of autograft. Platelet recovery was defined as the first day with an unsubstituted platelet count above 20000/µL from the day of autograft. The observation period was from high-dose therapy until the patients left the hospital. The assessment of infection was carried out according to previously published criteria (Link et al. 1994 ).
Objectives and statistical analysis
The objectives of this investigation were to correlate the WBC peak as the indicator of G-CSF responsiveness with the neutrophil and platelet recovery and the rate and type of infection and to compare these correlations with those obtained for the CD34 + cell number in the autologous blood stem cell autograft. All analyses presented (except for the demographic and disease baseline characteristics) are based on transplantation courses as units of observation.
For
The rates of neutrophil and platelet recovery over time were estimated using the product-limit method according to Kaplan and Meier (Kaplan and Meier, 1958 ) and prognostic subgroups were compared by use of the log-rank test (Peto and Peto, 1972 ).
Fisher's exact or chi 2 tests for trend were applied in the analyses of rates. In order to examine the independent impact of the prognostic factors with regard to the different end-points, multivariate analyses were carried out with Cox (Cox, 1972) or logistic regression models depending on the nature of the outcome variable, including all parameters with a p-value <0.1 in univariate analysis. Model reduction was performed in a step-wise manner, excluding parameters with a p-value >0.1. All reported p-values result from two-sided tests.
Results
Host responsiveness to G-CSF
A single subcutaneous G-CSF injection (5 µg/kg) was administered early after 85 highdose chemotherapy (melphalan 200 mg/m 2 ) courses in 57 patients with multiple myeloma. At this time point, the median white blood cell (WBC) count was 4000/µL (range 1800-10100/µL) after a first high-dose chemotherapy course (n=50) and 4700/µL (range 1900-9300/µL) after a second course (n=35). The G-CSF induced WBC peak was measured 12-14 hours later. These transient WBC peaks had a variable magnitude and consisted of more than 90% neutrophils. Colony-forming cells or CD34 + cells were not detected within these WBC peaks. The WBC peaks were higher after a first highdose chemotherapy with a median of 21000/µL (range 6400-60600/µL) compared with a median of 13500/µL (range 4700-24800/µL) after the second course. Different levels of G-CSF responsiveness (low, medium, high) were defined based on the terciles of the WBC peak distributions separately for a first and a second high-dose treatment ( figure   2 ). Subsequent to the highly variable WBC peak, the WBC counts decreased to the leukocyte nadir. Severe leukopenia (<200/µL) was present in all cases and was terminated by leukocyte engraftment. The course of the median WBC count for the different levels of G-CSF responsiveness is shown in figure 1 . and table 1) . A low G-CSF responsiveness was present in 70 % of patients with a documented infection. There was virtually no correlation for the occurrence of infection in the same patient when two transplants were performed. In the 27 patients with both a first and a second high-dose treatment in the data set, the 16 infections during the respective 54 (2 x 27) high-dose chemotherapy courses occurred in 13 different patients. Neutropenia <500/µL lasted for a median of 5 days (3-9 days). As has to be expected, also the duration of neutropenia was associated with the rate of documented infections (p=0.011; Fisher's exact test) (table 1) . In logistic regression analysis, the association between G-CSF responsiveness and the occurrence of infection was significant after adjustment for neutropenia duration and G-CSF responsiveness was the more informative parameter in this multivariate analysis. The odds ratios (95 %CI) for G-CSF responsiveness (>median) and duration of neutropenia <500/µL (≤ 5 days)
Occurrence of infection
were 0.22 (0.072-0.70) (p=0.010) and 0.33 (0.12-0.95) (p=0.040). In a subgroup analysis which separated the cases with a short (≤ 5 days) from the cases with a longer (>5 days) duration of neutropenia, the cases with higher G-CSF responsiveness showed a reduced risk of infection also with a longer duration of neutropenia (figure 3). When specifying the different types of documented infection, it turned out that the majority of pneumonias and all the invasive fungal infections and treatment-related deaths occurred in patients with a low G-CSF responsiveness (table 2) .
13
There was no association between the rate of documented infection and the number of transplanted CD34 + cells ( figure 2B and table 1) . None of the parameters presented in table 1 showed a significant association with fever.
The influence of patient characteristics and treatment
For age, gender, radiotherapy and the WBC count before G-CSF no significant influence on stem cell engraftment and infection was found in univariate analyses (table   1) . For neutrophil engraftment, a negative trend for an association with months of prior alkylating chemotherapy (p=0.091) and a negative association with the number of leukapheresis harvests which were required to harvest the target CD34 + cell number (p=0.001) was found. For the occurrence of infection, a trend for an association with more cycles of chemotherapy before stem cell transplant was found (p=0.081). These factors were included in the respective multivariate analyses but did not reach statistical significance.
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Discussion
In this investigation we found that host responsiveness to a single dose of pharmacological G-CSF showed a dominant association with the risk of infection in high-dose chemotherapy recipients. Also, the responsiveness to G-CSF gave additional information about the time to stem cell engraftment. Controlled clinical trials on risk-stratified supportive care are warranted in multiple myeloma and G-CSF responsiveness could provide a novel basis for this (Meisenberg et al. 1997; Herrmann et al. 1999 , Kern et al. 1999 Freifeld et al. 1999 ). Also, it will be interesting to see how general a role for G-CSF responsiveness can be found in other diseases like leukemia and whether G-CSF responsiveness can define the requirements for pharmacological G-CSF therapy.
